Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease
Status:
Completed
Trial end date:
2021-06-22
Target enrollment:
Participant gender:
Summary
This pilot trial offers the unique opportunity for both the treatment of multiple myeloma or
systemic AL amyloidosis for which hematopoietic stem cell transplantation would be ordinarily
indicated and the reversal of end-stage renal failure, while avoiding the risks associated
with long-term standard anti-rejection therapy used in renal transplantation. The primary
objectives of this study are to assess renal allograft tolerance (that is, the acceptance of
the kidney without the need for anti-rejection therapy), assess anti-tumor response rates in
multiple myeloma and AL amyloidosis, and assess complication rates for genetically (HLA)
matched related donor combined bone marrow and kidney transplantation using a low dose total
body irradiation based preparative regimen.